NCT07625553 R2R01 Acute Kidney Injury Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Turn a newly registered trial into a decision-ready clinical landscape. This report examines NCT07625553 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.

MCP evidence snapshot: 23 July 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.

Why NCT07625553 is a hot trial to watch

Acute Kidney Injury is being segmented by mechanism, treatment setting, geography and endpoint architecture. NCT07625553 is notable because it evaluates R2R01 in a Phase 2 design sponsored by River 2 Renal Corp.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.

Trial landscape snapshot

Protocol design and endpoint interpretation

This is a Phase 2, dose-ranging, double-blind, double-dummy, placebo-controlled, randomized study preceded by an open label safety run-in, in patients at high risk for Cardiac Surgery Associated - Acute Kidney Injury (CSA-AKI) following coronary artery bypass graft (CABG), valve surgery, aortic surgery, or a combination of the above, involving cardiopulmonary bypass (CPB). Subjects are eligible for screening if they are scheduled for non-emergent CABG, valve surgery, surgery of the ascending part of the aorta, or a combination of the above, involving CPB, within 4 weeks after screening. In addition, subjects are eligible if AKI risk factors are present (at screening): a. If isolated surgery (CABG, single valve surgery, or of the ascending part of the aorta surgery) is scheduled, at least two AKI risk factors should be present b. If combined surgery is scheduled, at least one AKI risk factor should be present Risk factors for AKI are def

Allocation is Randomized, masking is Double, and the intervention model is Parallel Assignment. Planned enrollment of [object Object] participants across Italy shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.

• The safety and efficacy of R2R01 for prevention of AKI (Proportion of subjects deve) after cardiac surgery (CABG, valve surgery, aortic surgery, or a combination of the above) involving CPB, in subjects with additional risk factors for developing CSA-AKI (18 months) — The outcome will be measured as: • Nature, of treatment-emergent adverse events (TEAEs).
• The safety and efficacy of R2R01 for prevention of AKI (Proportion of subjects deve) after cardiac surgery (CABG, valve surgery, aortic surgery, or a combination of the above) involving CPB, in subjects with additional risk factors for developing CSA- (18 months) — The outcome will be measured as frequency of treatment-emergent adverse events (TEAEs).
• The safety and efficacy of R2R01 for prevention of AKI (Proportion of subjects deve) after cardiac surgery (CABG, valve surgery, aortic surgery, or a combination of the above) involving CPB, in subjects with additional risk factors for developing CSA-AKI (18 months) — The outcome will be measured as severity of treatment-.emergent adverse events (TEAEs).

Readout outlook and evidence gap

The current protocol points to [object Object] as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.

Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset MCP profile: R2R01 is indexed as No normalized modality returned, with target No normalized target returned, mechanism No normalized mechanism returned, and global highest development status No normalized global status returned.

Company & Deal Intelligence MCP profile: River 2 Renal Corp. is resolved to a normalized organization record in United States. The organization workflow adds identity, location, portfolio and partnering context where available.

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
• Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.

Bottom line

NCT07625553 provides a focused lens on Acute Kidney Injury development. Its value will be determined by whether R2R01 can convert the current Phase 2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.